

Press Releases

All Years ▾
<input type="text" value="Search"/>
<input type="button" value="Go"/>

[Advanced Search](#)

DEC 9, 2009

[**Perrigo Confirms Filing for Generic Version of Clobex® Spray and Announcement of Lawsuit by Galderma and Dermalogix**](#)

DEC 7, 2009

[**Perrigo Company Launches Labeling Initiative to Identify Gluten-free Products**](#)

Gluten-free labeling program an industry first for over-the-counter pharmaceuticals

NOV 19, 2009

[**Perrigo Company To Present at the Sidoti Emerging Growth Conference**](#)

NOV 9, 2009

[**/CORRECTION – Perrigo Company/**](#)

In the news release, Perrigo Company to Present at the Credit Suisse 18th Annual Health Care Conference, issued 09-Nov-2009 by Perrigo Company over PR Newswire, we are advised by the company that in the first paragraph, the conference date and time should

NOV 9, 2009

[**Perrigo Company to Present at the Credit Suisse 18th Annual Health Care Conference**](#)

NOV 2, 2009

[Perrigo Reports Record Earnings and Raises Full Year Adjusted EPS Guidance](#)

NOV 2, 2009

[Perrigo Company Divests Israel Cosmetics Business for 205 Million New Israeli Shekels](#)

OCT 29, 2009

[Perrigo Company Announces Dividend Increase](#)

OCT 19, 2009

[Perrigo Company Will Release First Quarter Fiscal 2010 Results on November 2, 2009](#)

OCT 19, 2009

[Perrigo Announces Dismissal of Duac® Patent Litigation](#)

OCT 13, 2009

[Perrigo Confirms Filing for Generic Version of Men's Rogaine® Foam](#)

OCT 6, 2009

[Perrigo Announces FDA Final Approval for Polyethylene Glycol 3350](#)

SEP 21, 2009

[Perrigo Company To Host Investor Day](#)

SEP 21 2009

[JUN 24, 2009](#)

[Perrigo Acquires ANDA for Generic Version Duac® Gel From KV Pharmaceutical](#)

[AUG 18, 2009](#)

[Perrigo Reports Record Sales, Earnings and Cash Flow From Operations for Fiscal 2009](#)

- Full-year revenue from continuing operations increased \$277 million, or 16 percent, to a record \$2 billion - Adjusted income from continuing operations for the full year increased 13 percent to \$175 million, or \$1.87 per share - GAAP income from continu

[AUG 13, 2009](#)

[Perrigo Company Announces Quarterly Dividend](#)

[AUG 4, 2009](#)

[Perrigo Company Will Release Fiscal Year 2009 Results on August 18, 2009](#)

[AUG 3, 2009](#)

[Perrigo Announces FDA Approval for Generic Version of NASACORT® AQ](#)

[JUL 13, 2009](#)

[Perrigo Receives FDA Approval to Market Cherry and Cinnamon Flavored Nicotine Lozenges](#)

[JUN 24, 2009](#)

[Perrigo Confirms That its Partner Synthon Has Filed for Generic Version of Xyzal® Solution and Announcement of Lawsuit by Sepracor/UCB](#)

MAY 7, 2009

[Perrigo Reports Record Third Quarter](#)

MAY 6, 2009

[Perrigo Company Announces Quarterly Dividend](#)

MAR 24, 2009

[Perrigo Announces FDA Approval for Sulfacetamide Sodium Topical Suspension USP, 10% \(Lotion\)](#)

MAR 17, 2009

[Perrigo and Partner Cobrek Confirms Filing for Generic Version of Evoclin® and Announcement of Lawsuit by Stiefel](#)

FEB 20, 2009

[Perrigo Begins Shipments of Ibuprofen PM](#)

FEB 3, 2009

[Perrigo Reports Record Second Quarter Sales](#)

- Fiscal second quarter revenue increased \$126 million, or 29%, to \$561 million as compared to \$435 million this quarter a year ago

JAN 28, 2009

[Perrigo Company Announces Quarterly Dividend](#)

JAN 21, 2009

[Perrigo Company Will Release Second Quarter Fiscal Year 2009 Results on February 3, 2009](#)

JAN 7, 2009

[Perrigo Company to Present at the 27th Annual JPMorgan Healthcare Conference](#)

DEC 29, 2008

[Perrigo Announces FDA Final Approval for Ibuprofen PM](#)

DEC 4, 2008

[Perrigo Settles Desloratadine Patent Litigation](#)

NOV 19, 2008

[Perrigo Acknowledges Settlement of NASACORT® AQ Nasal Spray Patent Litigation](#)

NOV 13, 2008

[Perrigo Acquires Unico Holdings](#)

NOV 6, 2008

[Perrigo Reports Record First Quarter Sales and Income](#)

* Fiscal first quarter revenue of \$480 million represents an increase of \$97 million, or 25 percent, from first quarter last year

NOV 4, 2008

[Perrigo Company Announces Dividend Increase](#)

OCT 29, 2008

[Perrigo Announces FDA Tentative Approval for Ibuprofen PM](#)

OCT 23, 2008

[Perrigo Company will Release First Quarter Fiscal Year 2009 Results on November 6, 2008](#)

OCT 6, 2008

[Perrigo Acquires Mexican Manufacturer Laboratorios Diba, S.A.](#)

OCT 3, 2008

[Perrigo Company to Present at the JMP Securities 2008 Healthcare Focus Conference](#)

SEP 18, 2008

[Perrigo Dismissed from Miconazole Patent Litigation](#)

SEP 16, 2008

[Perrigo Acquires JB Laboratories](#)

SEP 15, 2008

[Perrigo Company To Present at the Merrill Lynch Global Pharmaceutical Conference](#)

SEP 8, 2008

[Perrigo Acquires Exclusive Sales and Distribution Rights to Allergy Drug Levocetirizine from Synthon](#)

AUG 18, 2008

[Perrigo Reports Record Sales, Earnings and Cash Flow from Operations for Fiscal 2008](#)

- Full year revenue increased \$375 million, or 26 percent, to a record \$1.8 billion, including \$500

million for the fourth quarter

AUG 13, 2008

[Perrigo Company Announces Quarterly Dividend](#)

AUG 11, 2008

[Perrigo Begins Shipments of Famotidine Complete to Customers Nationwide](#)

AUG 5, 2008

[/CORRECTION -- Perrigo Company/](#)

In the release, Perrigo Company to Present at the Bank of America Specialty Pharmaceuticals Conference, issued earlier today by Perrigo Company (Nasdaq: PRGO; TASE), over PR Newswire, we are advised by the Company that the first sentence of the first para

AUG 5, 2008

[Perrigo Company to Present at the Bank of America Specialty Pharmaceuticals Conference](#)

AUG 5, 2008

[Perrigo Company Will Release Fiscal Year 2008 Results on August 18, 2008](#)

JUL 15, 2008

[Perrigo to Grow in Michigan](#)

Company focused on producing quality, affordable healthcare

Show per page



<https://investor.perrigo.com/press-releases?l=50&o=700>